Skip to content
ApprovedFDA approved

Exemestane (Aromasin)

Prescription aromatase inhibitor for breast cancer that bodybuilders use to keep estrogen low; banned on the anti-doping list.

Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Exemestane (Aromasin) vial

DETAILED OVERVIEW

What is Exemestane (Aromasin)?

Exemestane (Aromasin) is a prescription medicine for estrogen-sensitive breast cancer in women after menopause. It has been approved in the United States since 1999, and in the EU as well. Bodybuilders and other athletes use it to keep estrogen low while taking muscle-building steroids. It is banned year-round on the anti-doping list.

It blocks an enzyme called aromatase, which makes estrogen from testosterone. It binds to the enzyme permanently and disables it, so the effect wears off only when the body has made new enzyme, which takes about 5–7 days. Typical side effects are joint and muscle pain, hot flashes and tiredness; if estrogen drops too far, low mood, reduced sex drive and erection problems can appear. It lowers HDL cholesterol and, with long-term use, raises the risk of bone thinning. It must not be used in pregnancy, because it can harm the baby.

Mechanism

Steroidal "suicide" (irreversible covalent) CYP19 aromatase inhibitor – a single dose permanently inactivates a portion of the pool

Half-life

~27 h (parent), ~24-48 h active metabolite; pharmacodynamic effect 5-7 days

Onset

E2 reduction measurable 12-24 h, full effect 3-5 days

Legal status

FDA + EMA Rx, HU + PL approved, WADA S4.1 banned

Data console

Lab data

Androgenic:AnabolicNegligible – 17-hydro-exemestane has mild AR affinity (~5% testosterone affinity), clinically negligible anabolic effect, BUT SHBG-lowering (measurable free-Test rise).
AR bindingCYP19 aromatase active-site irreversible covalent binding.…
Active half-life~24-48 h (17-hydro-exemestane); pharmacodynamic effect 5-7 days (irreversible enzyme inactivation)
Detection windowWADA-accredited GC-MS/LC-MS/MS urine detection ~1 month post-last dose.
AromatizationDoes not aromatize – steroidal "suicide inhibitor" (irreversible covalent CYP19 binding). The parent compound has a steroid structure (androstadiendione analog), not an agonist.
HepatotoxicityLow – steroid structure BUT NOT 17α-alkylated. Hepatic AE <2% (FDA Aromasin label). 17-hydro-metabolite mild AR activity does not pose clinically relevant hepatic stress.

Safety

Side effects, stop signs, contraindications

Side effects · 8

  • Joint and muscle pain (arthralgia, myalgia) and stiffness, a hallmark estrogen-deprivation effect of the AI class.
  • Hot flushes, sweating and fatigue, vasomotor symptoms of rapid estrogen decline.
  • Over-suppressed estradiol (crashed E2): low mood, reduced libido, dry/cracking joints, depression and erectile difficulty.
  • Adverse lipid shift: lowered HDL (~10-15%) and slight LDL rise, which compounds on top of an AAS stack.
  • Reduced bone mineral density (osteopenia/osteoporosis risk) and higher fracture tendency with prolonged estrogen suppression.
  • Mild androgenic effects from the 17-hydro-exemestane metabolite: acne and oily skin may increase, especially stacked with aromatizing steroids.
  • Headache, insomnia, dizziness and gastrointestinal complaints (nausea), common and usually mild.
  • Rarely elevated liver enzymes (ALT/AST) and bilirubin; as an oral agent, dual liver monitoring is warranted alongside 17-alpha-alkylated AAS.

Contraindications · 7

  • Pregnancy and breastfeeding: exemestane is teratogenic and fetotoxic (Pregnancy Category X), absolutely contraindicated.
  • Premenopausal women: ineffective due to intact ovarian aromatase and may cause ovulatory/hormonal disruption and virilization, contraindicated.
  • Known hypersensitivity to exemestane or any excipient of the formulation.
  • Severe hepatic (Child-Pugh C) or renal impairment: disturbed metabolism and clearance with increased exposure, caution/contraindication.
  • Pre-existing osteoporosis or high bone-loss risk: estrogen suppression accelerates bone loss, avoid without prior DEXA and bone protection.
  • Concurrent estrogen-containing agents (HRT, phytoestrogens): they negate the aromatase inhibition, an interaction to avoid.
  • Strong CYP3A4 inducers (rifampicin, carbamazepine, St. John's wort) reduce efficacy; avoid prophylactic AI use without E2 baseline bloodwork due to crashed-E2 risk.

Related Performance Compounds

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about Exemestane (Aromasin)?

Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.